X

The Lancet Oncology

The Lancet Oncology
Neural Stem Cell Delivery of an Oncolytic Adenovirus in Newly Diagnosed Malignant Glioma

Study investigators examine the safety and activity of NSC-CRAd-S-pk7, an engineered oncolytic adenovirus delivered by neural stem cells, in patients with newly diagnosed high-grade glioma.

The Lancet Oncology
06/29/2021
Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study investigators aim to evaluate the antitumour activity and safety of loncastuximab tesirine in patients with relapsed or refractory DLBCL.

The Lancet Oncology
06/01/2021
Avelumab Alone or in Combination With Chemotherapy versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Study investigators report results of avelumab alone or avelumab plus PLD compared with PLD alone in patients with platinum-resistant or platinum-refractory ovarian cancer.

The Lancet Oncology
06/15/2021
Chemotherapy De-escalation Using an 18F-FDG-PET-based Pathological Response-Adapted Strategy in Patients With HER2+ Early Breast Cancer

Study investigators assess early metabolic responses to neoadjuvant trastuzumab and pertuzumab using 18F-fluorodeoxyglucose and the possibility of chemotherapy de-escalation using...

The Lancet Oncology
05/18/2021
Pralsetinib for RET Fusion-Positive Non-Small-Cell Lung Cancer

Study investigators assess the safety, tolerability, and antitumour activity of pralsetinib, a highly potent, oral, selective RET inhibitor, in patients with RET fusion-positive NSCLC.

The Lancet Oncology
06/09/2021
Patient-Reported Outcomes With Atezolizumab Plus Bevacizumab versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma

Study investigators evaluate patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150 trial...

The Lancet Oncology
05/27/2021
Pembrolizumab Plus Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Given each drug's single agent activity and unique mechanism of action, this study aims to evaluate the anti-tumour activity of PD-1 blockade with EGFR inhibition in recurrent or metastatic HNSCC.<

The Lancet Oncology
05/11/2021
Efficacy and Safety of Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

This study evaluates the efficacy and safety of tisotumab vedotin, a tissue factor-directed antibody–drug conjugate, in this patient population.

The Lancet Oncology
05/01/2021
Second-Line FOLFOX Chemotherapy versus Active Symptom Control for Advanced Biliary Tract Cancer

The aim of this study is to determine the benefit derived from second-line FOLFOX chemotherapy in advanced biliary tract cancer.

The Lancet Oncology
05/01/2021
Safety and Immunogenicity of One versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients With Cancer

This study examines the safety and immunogenicity of the BNT162b2 vaccine in patients with cancer.

The Lancet Oncology
04/27/2021
Subscribe to The Lancet Oncology

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834